Amgen Completes $13.4 Billion Acquisition Of Otezla
socalTECH
NOVEMBER 22, 2019
Thousand Oaks-based biotech giant Amgen said Thursday that it has successfully completed its acquisition of the worldwide rights to Otezla , from Celgene Corporation , in a deal that was worth $13.4 Amgen also said the deal will push its total revenues for 2019 into the range of $23.1 billion in anticipated future cash tax benefits.
Let's personalize your content